-
Next month, GlaxoSmithKline's breathing lines will merge
Time of Update: 2021-02-28
breathing line news today has been officially informed, GlaxoSmithKline China has officially informed employees, from May 1, the respiratory business structure adjustment, specifically, the original innovative products and classic products combined
-
Tengsheng Bo Pharmaceuticals was established and received $260 million in financing from six well-known institutions
Time of Update: 2021-02-28
advanced technology and data to help the development of China's public health system, thereby benefiting the vast number of patients. First, in partnership with Vir Biotechnology, a leading U.S. infectious disease innovation drug developer
-
Whether the brain is aging is reversible depends on whether the environment is soft enough to grow
Time of Update: 2021-02-27
BEIJING, Aug. 15 (Xinhua ) -- British scientists writing in the 14th issue of nature say they have found a new way to reverse aging brain stem cells into younger, healthier states: growing on materials similar to the softness of young
-
Johnson and Johnson, Takeda and Evotec joined the Alzheimer's Alliance
Time of Update: 2021-02-26
The Dementia Alliance is a leading partner program that provides funding, industry expertise and project management resources to academic researchers to use new drug targets to treat neurodegenerative diseases that cause dementia.
-
Gilead Target has 500 million U.S. dollars in deals with Preciion BioSciences
Time of Update: 2021-02-26
The ARCUS platform is based on the natural genome editing enzyme home nucleic acid inchease, which identifies long DNA sequences.
-
Sanofi and MyoKardia ended their heart drug partnership
Time of Update: 2021-02-26
ended a four-year partnership between Sanofi and MyoKardia to develop small molecule therapies for genetic mutations associated with certain heart diseases. By the end of the deal in April, MyoKardia will regain full rights
-
JAHA: Plate plate rest therapy in patients with acute coronary artery syndrome who received coronary artery bridge
Time of Update: 2021-02-26
meta-analysis, the researchers compared patients with coronary arterial bridge surgery who had received more effective antiplate plateplate suppression strategies and less effective plateplate suppression strategies, respectively.
-
Frequency Therapeutics completed a $62 million round C financing
Time of Update: 2021-02-26
agreement with Astellas Pharma for global development of FX-322, which includes $80 million in advance payments and $545 million in sales. “ This financing comes at an important time for Freequency as we prepare to advance our
-
AP-T: Compared to endoscopic mucosa healing in Crohn's disease, intestinal permeable wall healing and MRI healing are associated with a lower risk of progression of intestinal damage
Time of Update: 2021-02-26
and permeable wall therapy of 51.9% (80/154), 10.4% (16/154), 19.5% (30/154) and 18.2% (28/154) cures, respectively. the risk of intestinal damage is lower than that of permeable wall healing (HR s 0.05 s 0.00-0.40, P s 0.002) and MRI healing (HR s
-
Br J Cancer: Multigene testing guides chemotherapy recommendations for breast cancer
Time of Update: 2021-02-26
Therefore, the study aims to develop health care recommendations on whether the use of multigene testing can guide the development of complementary chemotherapy in patients with early-stage immersive breast cancer, hormone-positive, HER2-negative patients.
-
Frontier Medicines completed a $67 million round of A financing
Time of Update: 2021-02-26
$67 million round of financing for frontier Pharmaceuticals, a biopharmaceutical company, on June 25, local time. This round of financing will be used to support the company's development of a variety of protein target drugs.
-
AstraZeneta pioneered the Lung Cancer Alliance to improve survival
Time of Update: 2021-02-26
in 2014 and has since launched a range of new drugs, including Imfinzi, Calquence, Lynparza and Tagrisso. In the area of lung cancer, the PD-L1 drug Imfinzi was approved for the treatment of stage III lung cancer that could not be surgically removed, while Tagrisso was approved for the treatment of non-small cell lung cancer with EGFR mutations. （cyy123.com）
-
Grigg Ingham will acquire Vira Therapeutics
Time of Update: 2021-02-26
the team specializes in the development of lysovirus therapies, and its main candidate is VSV-GP (blistered oral inflammatory virus (VSV) with modified glycoprotein (GP), which is being studied separately and used in combination with other therapies.
-
Crit Care: Clinical significance of the density of copper-green false monocytobacteria in the airfra of mechanically breathing patients
Time of Update: 2021-02-24
analysis of propensity score matching showed that in the peak density group of copper-green false monocytobacteria, patients with ventilator-related tracheitis were treated with antibiotics to improve mechanical ventilators.
-
The Cotton Rat as a Model for Staphylococcus aureus 19 Nasal Colonization in Humans: Cotton Rat S. aureus Nasal Colonization Model
Time of Update: 2021-02-24
Further, the cotton rat model allows for assessment of the ability of defined genetic mutants ofS.
-
Dig Dis Sci: Colonoscopic fecal microbiota transplantation (FMT) is superior to the way enemas and nasal gastric tubes treat difficult Thyrobacteria refractive infections
Time of Update: 2021-02-24
study aims to assess differences in the efficacy of relapse CDI in four ways of colonoscopic infusion, capsule, enema and nasal gastric tube (NGT).
-
Nat Commun: CAR-T cells enhance the efficacy of immunotherapy by mediating the depletion of macrophages associated with immunosuppressive tumors
Time of Update: 2021-02-24
as an alternative to CAR-T therapy, which directly targets cancer cells, targeting TME non-tumor components has become an indirect treatment to limit tumor development.
-
Nat Commun: The absence of BCMA's double allegiant gene in patients with multiple myeloma causes the development of drug resistance in CAR-T therapy
Time of Update: 2021-02-24
Targeted BCMA (B-cell mature antigen) inlay antigen-subject (CAR) T-cell therapy has now shown far-reaching and long-lasting response effects in recurring refractic multiple myeloma (MM), the initial Phase I/II study showed that the therapy has
-
JAHA: The relationship between common drugs and cerebral hemorrhage
Time of Update: 2021-02-24
in the adjusted model, CMB was not associated with the use of antiplate plateplates, anticoagulants, or statins.
-
Rinvoq has been approved by the European Union to treat rheumatoid arthritis
Time of Update: 2021-02-24
) to treat adult patients with moderate to severe active rheumatoid arthritis who do not respond adequately or to the MTX. Currently, an estimated 400,000 people in the UK suffer from rheumatoid arthritis, most of whom are not in remission. （cyy123.com）
